Why the study?
Does rosiglitazone reduce hypercholesterolaemia-induced MPO upregulation and myocardial infarct size in a rabbit model of ischaemia/reperfusion?
Population
Male New Zealand rabbits fed with a normal or a high-cholesterol diet for 8 weeks, subjected to myocardial…
Comparison
Rosiglitazone 3 mg/kg/day for the last 5 weeks vs Vehicle
Design
Preclinical
Follow-up
8 weeks
Authors
Loading...
Rosiglitazone attenuates hypercholesterolaemia-induced injury in rabbit I/R; hypothesis-generating, should not change practice.
Does rosiglitazone reduce hypercholesterolaemia-induced MPO upregulation and myocardial infarct size in a rabbit model of ischaemia/reperfusion?
Rosiglitazone reduces myocardial infarct size and caspase-3 activity by inhibiting hypercholesterolaemia-induced MPO overexpression in a rabbit model of ischaemia/reperfusion.
Liu et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: